{"id":14671,"date":"2026-06-03T12:04:49","date_gmt":"2026-06-03T12:04:49","guid":{"rendered":"https:\/\/lemonn.co.in\/blog\/?p=14671"},"modified":"2026-06-03T12:04:57","modified_gmt":"2026-06-03T12:04:57","slug":"concord-biotech-price-jump-usfda","status":"publish","type":"post","link":"https:\/\/lemonn.co.in\/blog\/market-updates\/concord-biotech-price-jump-usfda\/","title":{"rendered":"Concord Biotech jumps on USFDA nod for transplant drug"},"content":{"rendered":"
\"Concord<\/figure>\n\n\n

Concord Biotech<\/strong> shares extended gains this week after the company received US Food and Drug Administration approval for its mycophenolate mofetil oral suspension, tapping an estimated $30 million<\/strong> US immunosuppressant market. The stock rallied despite a weak March quarter, with investors betting the new product will support the company\u2019s US and international growth plans.<\/p>\n\n\n\n

Market overview: Concord Biotech price jump<\/h2>\n\n\n\n
Metric<\/strong><\/th>Detail<\/strong><\/th><\/tr><\/thead>
Latest intraday move (Wednesday)<\/td>Shares up as much as 8.46%<\/strong>, intraday high at \u20b91,264.90<\/strong><\/td><\/tr>
Previous session close (Tuesday)<\/td>Ended 11.18%<\/strong> higher at \u20b91,180<\/strong><\/td><\/tr>
Earlier close (BSE reference)**<\/td>\u20b91,166.80<\/strong>, up \u20b9106.20<\/strong> or 10.01%<\/strong> on June 2<\/td><\/tr>
52-week high<\/td>\u20b92,150<\/strong><\/td><\/tr>
52-week low<\/td>\u20b9987<\/strong><\/td><\/tr>
Market capitalisation<\/td>Approx. \u20b912,200 crore<\/strong><\/td><\/tr>
Year-to-date performance<\/td>Stock down about 12%<\/strong> in 2026 despite recent rally<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
    \n
  • Concord Biotech shares reacted to the USFDA approval for a key transplant drug.<\/li>\n\n\n\n
  • The price jump followed two consecutive strong sessions on June 2 and June 3.<\/li>\n\n\n\n
  • Despite the rebound, the stock trades well below its 52-week high of \u20b92,150.<\/li>\n<\/ul>\n\n\n\n

    USFDA approval and product details<\/h2>\n\n\n\n
    Aspect<\/strong><\/th>Detail<\/strong><\/th><\/tr><\/thead>
    Regulator<\/td>U.S. Food and Drug Administration (USFDA)<\/td><\/tr>
    Approval type<\/td>Abbreviated New Drug Application (ANDA)<\/td><\/tr>
    Product<\/td>Mycophenolate mofetil for oral suspension USP, 200 mg\/mL<\/strong><\/td><\/tr>
    Therapeutic class<\/td>Antimetabolite immunosuppressant<\/td><\/tr>
    Indication<\/td>Prophylaxis of organ rejection in kidney, heart, liver transplants<\/td><\/tr>
    Patient group<\/td>Adult and paediatric patients 3 months and older<\/strong><\/td><\/tr>
    Use<\/td>In combination with other immunosuppressive therapies<\/td><\/tr>
    Estimated US market size<\/td>Approx. $30 million<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
      \n
    • The company said the approval aligns with its long-term growth strategy.<\/li>\n\n\n\n
    • Concord expects the product to strengthen its US portfolio and transplant franchise.<\/li>\n\n\n\n
    • The company plans to leverage the approval to expand across US and other regulated markets.<\/li>\n\n\n\n
    • There were no withdrawal, cancellation, or suspension actions tied to the approval.<\/li>\n<\/ul>\n\n\n\n

      Financial performance and dividend<\/h2>\n\n\n\n
      Metric (Q4)<\/strong><\/th>Current<\/strong><\/th>Year-ago<\/strong><\/th>Change<\/strong><\/th><\/tr><\/thead>
      Net profit<\/td>\u20b988.8 crore<\/strong><\/td>\u20b9140.4 crore<\/td>-36.8%<\/strong><\/td><\/tr>
      Revenue from operations<\/td>\u20b9326.1 crore<\/strong><\/td>\u20b9429.9 crore<\/td>-24.1%<\/strong><\/td><\/tr>
      EBITDA<\/td>\u20b9118.5 crore<\/strong><\/td>\u20b9190.4 crore*<\/td>-37.8%<\/strong><\/td><\/tr>
      EBITDA margin<\/td>36.4%<\/strong><\/td>44.3%<\/td>Margin contraction<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

      *EBITDA base derived from stated percentage decline.<\/p>\n\n\n\n

        \n
      • The company cited lower revenue and margin contraction for the profit decline.<\/li>\n\n\n\n
      • Concord Biotech remains positioned as an R&D-driven biopharmaceutical player.<\/li>\n\n\n\n
      • Board recommended a dividend of \u20b97.55 per share<\/strong> (face value \u20b91) for FY26.<\/li>\n\n\n\n
      • Record date for dividend eligibility is 24 July 2026<\/strong>, subject to shareholder approval.<\/li>\n<\/ul>\n\n\n\n

        Technical and valuation snapshot<\/h2>\n\n\n\n
        Indicator<\/strong><\/th>Value<\/strong><\/th>Context<\/strong><\/th><\/tr><\/thead>
        Relative Strength Index (RSI-14)<\/td>56.2<\/strong><\/td>Indicates neutral to positive momentum<\/td><\/tr>
        Simple moving averages<\/td>Above 6 of 8<\/strong> key SMAs<\/td>Suggests broadly positive trend setup<\/td><\/tr>
        Price-to-earnings (P\/E)<\/td>42.56<\/strong><\/td>Reflects premium valuation for growth profile<\/td><\/tr>
        Price-to-book (P\/B)<\/td>6.13<\/strong><\/td>Indicates rich pricing versus book value<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
          \n
        • The stock\u2019s RSI level stays below the typical overbought threshold of 70.<\/li>\n\n\n\n
        • Trading above most key SMAs signals improving technical structure after recent gains.<\/li>\n<\/ul>\n\n\n\n